Lucy R Williams

Dr. Lucy R Williams


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
NINatsuko Imai
Natsuko Imai
AHAlexandra Hogan
Alexandra Hogan
LWLucy R Williams
Lucy R Williams
ACAnne Cori
Anne Cori
TMTara D. Mangal
Tara D. Mangal
NFNeil M. Ferguson
Neil M. Ferguson
Background: The multiple efficacious vaccines authorised for emergency use worldwide represent the first preventative intervention against coronavirus disease 2019 (COVID-19) that does not rely on social distancing measures. The speed at which data are emerging and the heterogeneities in study design, target populations, and implementation make it challenging to interpret and assess the likely impact of vaccine campaigns on local epidemics. We reviewed available vaccine efficacy and effectiveness studies to generate working estimates that can be used to parameterise simulation studies of vaccine impact. Methods: We searched MEDLINE, the World Health Organization’s Institutional Repository for Information Sharing, medRxiv, and vaccine manufacturer websites for studies that evaluated the emerging data on COVID-19 vaccine efficacy and effectiveness. Studies providing an estimate of the efficacy or effectiveness of a COVID-19 vaccine using disaggregated data against SARS-CoV-2 infection, symptomatic disease, severe disease, death, or transmission were included. We extracted information on study population, variants of concern (VOC), vaccine platform, dose schedule, study endpoints, and measures of impact. We applied an evidence synthesis approach to capture a range of plausible and consistent parameters for vaccine efficacy and effectiveness that can be used to inform and explore a variety of vaccination strategies as the COVID-19 pandemic evolves. Results: Of the 602 articles and reports identified, 53 were included in the analysis. The availability of vaccine efficacy and effectiveness estimates varied by vaccine and were limited for VOCs. Estimates for non-primary endpoints such as effectiveness against infection and onward transmission were sparse. Synthesised estimates were relatively consistent for the same vaccine platform for wild-type, but was more variable for VOCs. Conclusions: Assessment of efficacy and effectiveness of COVID-19 vaccines is complex. Simulation studies must acknowledge and capture the uncertainty in vaccine effectiveness to robustly explore and inform vaccination policies and policy around the lifting of non-pharmaceutical interventions.

26 October 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LWLucy R Williams
Lucy R Williams
NFNeil M Ferguson
Neil M Ferguson
CDChristl A Donnelly
Christl A Donnelly
NGNicholas C Grassly
Nicholas C Grassly
Background: Phase III trials have estimated coronavirus disease 2019 (COVID-19) vaccine efficacy (VE) against symptomatic and asymptomatic infection. We explore the direction and magnitude of potential biases in these estimates and their implications for vaccine protection against infection and against disease in breakthrough infections. Methods: We developed a mathematical model that accounts for natural and vaccine-induced immunity, changes in serostatus, and imperfect sensitivity and specificity of tests for infection and antibodies. We estimated expected biases in VE against symptomatic, asymptomatic, and any severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and against disease following infection for a range of vaccine characteristics and measurement approaches, and the likely overall biases for published trial results that included asymptomatic infections. Results: VE against asymptomatic infection measured by polymerase chain reaction (PCR) or serology is expected to be low or negative for vaccines that prevent disease but not infection. VE against any infection is overestimated when asymptomatic infections are less likely to be detected than symptomatic infections and the vaccine protects against symptom development. A competing bias toward underestimation arises for estimates based on tests with imperfect specificity, especially when testing is performed frequently. Our model indicates considerable uncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against any infection, with slightly higher than published, bias-adjusted values of 59.0% (95% uncertainty interval [UI] 38.4–77.1) and 70.9% (95% UI 49.8–80.7), respectively. Conclusions: Multiple biases are likely to influence COVID-19 VE estimates, potentially explaining the observed difference between ChAdOx1 and Ad26.COV2.S vaccines. These biases should be considered when interpreting both efficacy and effectiveness study results.

27 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
LWLucy R Williams
Lucy R Williams
JHJoachim Hombach
Joachim Hombach
Melanie MartiMelanie Marti
Melanie Marti
Background: Herpes zoster (HZ) is a painful neurocutaneous disease caused by the varicella-zoster virus. The recombinant zoster vaccine (RZV) is becoming increasingly incorporated into national vaccination schedules. We aimed to evaluate RZV from a global public health policy perspective. Methods: We performed a rapid review of studies evaluating the immunogenicity, efficacy, and effectiveness of RZV for protection against HZ and associated complications. We searched PubMed for English-language studies published between 7 August 2012 and 30 September 2023. Included studies reported vaccine efficacy or effectiveness against HZ and HZ-associated complications. Immunogenicity studies were included if they contributed to the understanding of RZV protection over time and/or co-administration with other vaccines. HZ outcomes were stratified by socio-demographic and clinical variables. Results: From 405 identified publications, 33 were eligible for the study. Most studies were conducted in the US (N = 12), across North America (N = 10), and Europe (N = 5), or across multiple locations across North America, Latin America, and Asia–Australia (N = 6). Vaccine efficacy against HZ in immunocompetent populations ranged between 90% and 97%, while effectiveness ranged between 71% and 86%. Protection stayed above 70% for at least 10 years, with no significant differences by age or ethnicity. Conclusions: RZV is effective in reducing the risk of HZ and its associated complications. Protection is long-lasting and the vaccine is suitable for older and immunocompromised populations. However, the decision to incorporate the vaccine into national policies depends on additional factors (e.g., cost-effectiveness), which may be difficult to characterize without an understanding of the global disease burden.

26 July 2024 in Vaccine
Verified
Journal Article
Open access
LWLucy R Williams
Lucy R Williams
KEKatherine R.W. Emary
Katherine R.W. Emary
DPDaniel J. Phillips
Daniel J. Phillips
JHJodie Hay
Jodie Hay
JLJessica P.J. Larwood
Jessica P.J. Larwood
MVMerryn Voysey
Merryn Voysey
Background: For pathogens which cause infections that present asymptomatically, evaluating vaccine efficacy (VE) against asymptomatic infection is important for understanding a vaccine's potential epidemiological impact. Regular testing for subclinical infections is a potentially valuable strategy but its success hinges on participant adherence and minimising false positives. This paper describes the implementation and adherence to weekly testing in a COVID-19 vaccine trial. Methods: COV002 was a phase 2/3 trial assessing the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Asymptomatic infections were detected using weekly self-administered swabs for RT-PCR testing. We analysed adherence using mixed-effects regression models and estimated the probability of true and false positive asymptomatic infections using estimates of adherence and testing characteristics. Findings: 356,551 tests were self-administered by 10,811 participants during the 13-month follow-up. Median adherence was 75.0% (IQR 42.6-90.9), which translated to a 74.5% (IQR 50.9-78.8) probability of detecting a positive asymptomatic infection during the swabbing period, and between 21 and 96 false positives during VE evaluation. The odds of returning a swab declined by 8% per week and further after testing positive and unblinding. Adherence was higher in older age groups, females and non-healthcare workers. Interpretation: The COV002 trial demonstrated the feasibility of running a long-term regular asymptomatic testing strategy. This information could be valuable for designing future phase III vaccine trials in which infection is an outcome. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, AstraZeneca.

29 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
LWLucy R Williams
Lucy R Williams
KEKatherine R W Emary
Katherine R W Emary
DPDaniel J Phillips
Daniel J Phillips
JHJodie Hay
Jodie Hay
JLJessica P J Larwood
Jessica P J Larwood
MVMerryn Voysey
Merryn Voysey
Background For pathogens which cause infections that present asymptomatically, evaluating vaccine efficacy (VE) against asymptomatic infection is important for understanding a vaccine’s potential epidemiological impact. Regular testing for subclinical infections is a potentially valuable strategy but its success hinges on participant adherence and minimising false positives. This paper describes the implementation and adherence to weekly testing in a COVID-19 vaccine trial. Methods COV002 was a phase 2/3 trial assessing the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Asymptomatic infections were detected using weekly self-administered swabs for RT-PCR testing. We analysed adherence using mixed-effects regression models and estimated the probability of true and false positive asymptomatic infections using estimates of adherence and testing characteristics. Findings 356,551 tests were self-administered by 10,811 participants during the 13-month follow-up. Median adherence was 75.0% (IQR 42·6-90·9), which translated to a 74·5% (IQR 50·9-78·8) probability of detecting a positive asymptomatic infection during the swabbing period, and between 21 and 96 false positives during VE evaluation. The odds of returning a swab declined by 8% per week and further after testing positive and unblinding. Adherence was higher in older age groups, females and non-healthcare workers. Interpretation The COV002 trial demonstrated the feasibility of running a long-term regular asymptomatic testing strategy. This information could be valuable for designing future phase III vaccine trials in which infection is an outcome. Funding UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland’s NIHR Clinical Research Network, AstraZeneca. Evidence before this study Regular testing for asymptomatic infections in clinical trials is useful for evaluating the role of candidate vaccines or drugs in preventing infection. While there is extensive research on loss to follow-up in clinical trials, there is minimal research on adherence to repeat clinical trial procedures. During the COVID-19 pandemic, regular asymptomatic testing was used for surveillance and contact tracing in isolated populations, and in two SARS-CoV-2 vaccine trials. We searched PubMed from database inception to Dec 17, 2023 using the following search terms (title or abstract) for articles published in English: (Adherence OR Compliance OR Uptake OR Implementation) AND (Repeat test* OR regular test* OR weekly test* OR monthly test* OR serial test*) AND (“covid*” OR “COVID-19*” OR “SARS-CoV-2*” OR “Severe Acute Respiratory Syndrome Coronavirus 2”), and reviewed the identified publications. Identified studies demonstrated the feasibility over short time periods of regular asymptomatic testing in hospital, care home, university, school and workplace settings. A small number evaluated differences in adherence by socio-demographic characteristics, mainly highlighting increased age as a predictor of adherence. No studies evaluated adherence in clinical trial settings or predictors of adherence over time. Added value of this study We evaluated the feasibility and adherence to regular asymptomatic testing in a phase III trial of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. We demonstrated high adherence across trial participants over a year of follow-up, but significant differences across socio-demographic characteristics. Adherence was highest in older age groups, females and non-healthcare workers, and declined most strongly over time in younger age groups. We show how the frequency of testing can be translated to an estimated probability of a false positive and negative infections. Implications of all the available evidence The overall evidence suggests that regular asymptomatic testing is a feasible strategy for tracking the risk of infection for diseases with a high proportion of subclinical infections. Strategies to support subpopulations to maintain adherence over prolonged periods of time may be necessary, and consideration needs to be given to the optimal time over which this type of intensive sampling provides valuable data. Further research into the effect of variation in adherence to regular testing on vaccine efficacy estimates would be valuable.

31 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LWLucy R Williams
Lucy R Williams
NFNeil M. Ferguson
Neil M. Ferguson
CDChristl A Donnelly
Christl A Donnelly
NGNicholas C. Grassly
Nicholas C. Grassly
Background Phase III trials have estimated COVID-19 vaccine efficacy (VE) against symptomatic and asymptomatic infection. We explore the direction and magnitude of potential biases in these estimates and their implications for vaccine protection against infection and against disease in breakthrough infections. Methods We developed a mathematical model that accounts for natural and vaccine-induced immunity, changes in serostatus and imperfect sensitivity and specificity of tests for infection and antibodies. We estimated expected biases in VE against symptomatic, asymptomatic and any SARS-CoV-2 infections and against disease following infection for a range of vaccine characteristics and measurement approaches, and the likely overall biases for published trial results that included asymptomatic infections. Results VE against asymptomatic infection measured by PCR or serology is expected to be low or negative for vaccines that prevent disease but not infection. VE against any infection is overestimated when asymptomatic infections are less likely to be detected than symptomatic infections and the vaccine protects against symptom development. A competing bias towards underestimation arises for estimates based on tests with imperfect specificity, especially when testing is performed frequently. Our model indicates considerable uncertainty in Oxford-AstraZeneca ChAdOx1 and Janssen Ad26.COV2.S VE against any infection, with slightly higher than published, bias-adjusted values of 59.0% (95% uncertainty interval [UI] 38.4 to 77.1) and 70.9% (95% UI 49.8 to 80.7) respectively. Conclusion Multiple biases are likely to influence COVID-19 VE estimates, potentially explaining the observed difference between ChAdOx1 and Ad26.COV2.S vaccines. These biases should be considered when interpreting both efficacy and effectiveness study results.